Table 3.

Associations of seven SNPs with platinum-based chemotherapy toxicity in the 403 NSCLC patients

Gene SNP	Genotype	Hepatotoxicity
		Grade 1–2 [cases (%)]	Grade 3–4 [cases (%)]	Additive model		Dominant model		Recessive model
				OR (95% CI)	P	OR (95% CI)	P	OR (95% CI)	P
Total		348	55
OCT2
rs316003	CC	18 (5.2)	1 (1.8)	0.61 (0.34–1.08)	0.089	0.59 (0.31–1.12)	0.109	0.37 (0.05–2.83)	0.336
	CT	120 (34.5)	14 (25.5)
	TT	298 (85.6)	37 (67.3)
rs316019	TT	9 (2.6)	0 (0.0)	0.42 (0.20–0.90)	0.026	0.42 (0.19–0.93)	0.033	0.00	0.998
	GT	87 (25.0)	8 (14.5)
	GG	239 (68.7)	45 (81.8)
ABCB1
rs1045642	TT	51 (14.7)	6 (10.9)	0.81 (0.52–1.26)	0.354	0.75 (0.42–1.35)	0.337	0.81 (0.32–2.01)	0.643
	CT	165 (47.4)	24 (43.6)
	CC	126 (36.2)	24 (43.6)
ABCC2
rs717620	AA	10 (2.9)	2 (3.6)	0.93 (0.54–1.59)	0.782	0.89 (0.48–1.66)	0.712	1.11 (0.23–5.44)	0.895
	AG	104 (29.9)	15 (27.3)
	GG	216 (62.1)	38 (69.1)
rs2273697	AA	2 (0.6)	0 (0.0)	1.15 (0.58–2.28)	0.682	1.20 (0.59–2.44)	0.608	0.00	0.999
	AG	60 (17.2)	12 (21.8)
	GG	285 (81.9)	43 (78.2)
rs3740066	AA	12 (3.4)	2 (3.6)	0.69 (0.38–1.23)	0.206	0.60 (0.31–1.17)	0.134	1.04 (0.22–4.92)	0.958
	AG	113 (32.5)	11 (20.0)
	GG	213 (61.2)	39 (70.9)
MATE1
rs2289669	AA	79 (22.7)	10 (18.2)	0.86 (0.56–1.33)	0.500	0.92 (0.46–1.82)	0.804	0.73 (0.35–1.53)	0.402
	AG	175 (50.3)	30 (54.5)
	GG	80 (23.0)	13 (23.6)

Gene SNP	Genotype	Gastrointestinal toxicity
		Grade 1–2 [cases (%)]	Grade 3–4 [cases (%)]c	Additive model		Dominant model		Recessive model
				OR (95% CI)	P	OR (95% CI)	P	OR (95% CI)	P
Total		368	35
OCT2
rs316003	CC	17 (4.6)	2 (5.7)	1.27 (0.72–2.25)	0.412	1.40 (0.69–2.85)	0.357	1.14 (0.25–5.23)	0.870
	CT	120 (32.6)	14 (40.0)
	TT	217 (59.0)	18 (51.4)
rs316019	TT	8 (2.2)	1 (2.9)	0.49 (0.20–1.17)	0.106	0.39 (0.15–1.05)	0.062	1.16 (0.14–9.74)	0.893
	GT	91 (24.7)	4 (11.4)
	GG	254 (69.0)	30 (85.7)
ABCB1
rs1045642	TT	52 (14.1)	5 (14.3)	0.71 (0.41–1.22)	0.217	0.54 (0.26–1.10)	0.091	0.96 (0.35–2.63)	0.941
	CT	177 (48.1)	12 (34.3)
	CC	133 (36.1)	17 (48.6)
ABCC2
rs717620	AA	11 (3.0)	1 (2.9)	0.79 (0.38–1.61)	0.510	0.73 (0.32–1.63)	0.438	1.09 (0.13–8.81)	0.939
	AG	111 (30.2)	8 (22.9)
	GG	231 (62.8)	23 (65.7)
rs2273697	AA	2 (0.5)	0 (0.0)	1.94 (0.93–4.04)	0.078	2.10 (0.97–4.53)	0.060	0.00	0.999
	AG	61 (16.6)	11 (31.4)
	GG	304 (82.6)	24 (68.6)
rs3740066	AA	12 (3.3)	2 (5.7)	0.91 (0.47–1.79)	0.795	0.76 (0.35–1.67)	0.500	2.25 (0.47–10.75)	0.309
	AG	116 (31.5)	8 (22.9)
	GG	229 (62.2)	23 (65.7)
MATE1
rs2289669	AA	79 (21.5)	10 (28.6)	1.35 (0.80–2.28)	0.254	1.55 (0.62–3.89)	0.350	1.44 (0.66–3.16)	0.363
	AG	187 (50.8)	18 (51.4)
	GG	87 (23.6)	6 (17.1)

Gene SNP	Genotype	Hematological toxicity
		Grade 1–2 [cases (%)]	Grade 3–4 [cases (%)]	Additive model		Dominant model		Recessive model
				OR (95% CI)	P	OR (95% CI)	P	OR (95% CI)	P
Total		308	95
OCT2
rs316003	CC	17 (5.5)	2 (2.1)	0.75 (0.49–1.15)	0.190	0.78 (0.47–1.28)	0.324	0.37 (0.08–1.67)	0.196
	CT	103 (33.4)	31 (32.6)
	TT	176 (57.1)	59 (62.1)
rs316019	TT	9 (2.9)	0 (0.0)	0.58 (0.34–0.97)	0.039	0.61 (0.34–1.07)	0.085	0.00	0.998
	GT	75 (24.4)	20 (21.1)
	GG	209 (67.9)	75 (78.9)
ABCB1
rs1045642	TT	44 (14.3)	13 (13.7)	0.92 (0.65–1.31)	0.648	0.87 (0.53–1.41)	0.560	0.97 (0.49–1.93)	0.936
	CT	147 (47.7)	42 (44.2)
	CC	111 (36.0)	39 (41.1)
ABCC2
rs717620	AA	8 (2.6)	4 (4.2)	1.15 (0.74–1.78)	0.546	1.09 (0.66–1.81)	0.736	1.88 (0.53–6.72)	0.330
	AG	91 (29.5)	28 (29.5)
	GG	196 (63.6)	58 (61.1)
rs2273697	AA	1 (0.3)	1 (1.1)	1.13 (0.64–1.98)	0.679	1.10 (0.60–1.99)	0.759	2.46 (0.15–40.00)	0.528
	AG	54 (17.5)	18 (18.9)
	GG	252 (81.8)	76 (80.0)
rs3740066	AA	12 (3.9)	2 (2.1)	0.89 (0.58–1.38)	0.600	0.94 (0.57–1.55)	0.806	0.49 (0.11–2.27)	0.361
	AG	94 (30.5)	30 (31.6)
	GG	192 (62.3)	60 (63.2)
MATE1
rs2289669	AA	58 (18.8)	31 (32.6)	1.30 (0.92–1.83)	0.141	0.99 (0.57–1.72)	0.973	1.92 (1.13–3.25)	0.016
	AG	164 (53.2)	41 (43.2)
	GG	70 (22.7)	23 (24.2)

Gene SNP	Genotype	Overall toxicity
		Grade 1–2 [cases (%)]	Grade 3–4 [cases (%)]	Additive model		Dominant model		Recessive model
				OR (95% CI)	P	OR (95% CI)	P	OR (95% CI)	P
Total		268	135
OCT2
rs316003	CC	14 (5.2)	5 (3.7)	0.85 (0.59–1.23)	0.400	0.86 (0.56–1.33)	0.502	0.66 (0.23–1.90)	0.446
	CT	91 (34.0)	43 (31.9)
	TT	154 (57.5)	81 (60.0)
rs316019	TT	8 (3.0)	1 (0.7)	0.59 (0.37–0.93)	0.024	0.59 (0.36–0.98)	0.041	0.21 (0.03–1.75)	0.150
	GT	68 (25.4)	27 (20.0)
	GG	179 (66.8)	105 (77.8)
ABCB1
rs1045642	TT	39 (14.6)	18 (13.3)	0.91 (0.67–1.24)	0.539	0.89 (0.58–1.38)	0.604	0.86 (0.47–1.58)	0.632
	CT	126 (47.0)	63 (46.7)
	CC	98 (36.6)	52 (38.5)
ABCC2
rs717620	AA	7 (2.6)	5 (3.7)	1.04 (0.70–1.54)	0.838	1.00 (0.63–1.56)	0.985	1.52 (0.47–4.91)	0.489
	AG	80 (29.9)	39 (28.9)
	GG	169 (63.1)	85 (63.0)
rs2273697	AA	1 (0.4)	1 (0.7)	1.49 (0.90–2.54)	0.118	1.50 (0.89–2.53)	0.128	2.30 (0.14–37.24)	0.557
	AG	42 (15.7)	30 (22.2)
	GG	224 (83.6)	104 (77.0)
rs3740066	AA	11 (4.1)	3 (2.2)	0.86 (0.58–1.27)	0.446	0.88 (0.56–1.37)	0.573	0.58 (0.16–2.12)	0.409
	AG	83 (31.0)	41 (30.4)
	GG	165 (61.6)	87 (64.4)
MATE1
rs2289669	AA	50 (18.7)	39 (28.9)	1.30 (1.00–1.86)	0.052	1.28 (0.77–2.13)	0.335	1.73 (1.06–2.82)	0.029
	AG	140 (52.2)	65 (48.1)
	GG	65 (24.3)	28 (20.7)

OCT2 organic cation transporter 2, ABCB1 ATP-binding cassette subfamily B member 1, ABCC2 ATP-binding cassette subfamily C member 2, MATE1 multidrug and toxin extrusion 1